Publications by authors named "Steven Shak"

Claim this Profile
R
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.
Yara Abdou, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Steven Shak

J Natl Cancer Inst· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer, Steven Shak

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.
Joseph A Sparano, Michael Crager, Robert J Gray, Gong Tang, Jess Hoag, Steven Shak

NEJM Evid· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer.
Soonmyung Paik, Gong Tang, Steven Shak, Chungyeul Kim, Joffre Baker

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
Corey W Speers, W Fraser Symmans, William E Barlow, Alex Trevarton, Stephanie The, Steven Shak

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
Melody A Cobleigh, Charles L Vogel, Debu Tripathy, Nicholas J Robert, Susy Scholl, Steven Shak

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of -Overexpressing Metastatic Breast Cancer.
Charles L Vogel, Melody A Cobleigh, Debu Tripathy, John C Gutheil, Lyndsay N Harris, Steven Shak

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Olga Kantor, Harold J Burstein, Tari A King, Steven Shak, Christy A Russell

Ann Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
Ulrike A Nitz, Oleg Gluz, Sherko Kümmel, Matthias Christgen, Michael Braun, Steven Shak

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kevin Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Steven Shak

N Engl J Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
Olga Kantor, Tari A King, Steven Shak, Christy A Russell, Armando E Giuliano

J Natl Cancer Inst· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to K. Ando et al.
Joseph A Sparano, Michael R Crager, Gong Tang, Robert J Gray, Salomon M Stemmer, Steven Shak

J Clin Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
Joseph A Sparano, Michael R Crager, Gong Tang, Robert J Gray, Salomon M Stemmer, Steven Shak

J Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ulrike Nitz, Oleg Gluz, Hans H Kreipe, Matthias Christgen, Sherko Kuemmel, Steven Shak

Ther Adv Med Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Wendy A Woodward, William E Barlow, Reshma Jagsi, Thomas A Buchholz, Steven Shak

JAMA Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Salomon M Stemmer, Mariana Steiner, Shulamith Rizel, Noa Ben-Baruch, Beatrice Uziely, Steven Shak

NPJ Breast Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E Kates, Michael Clemens, Steven Shak

Breast Cancer Res Treat· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Ulrike Nitz, Oleg Gluz, Michael Clemens, Wolfram Malter, Toralf Reimer, Steven Shak

J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Charles E Geyer, Gong Tang, Eleftherios P Mamounas, Priya Rastogi, Soonmyung Paik, Steven Shak

NPJ Breast Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, Nadia Howlader, Nathan Gliner, Will Howe, Steven Shak

NPJ Breast Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Characterization and Mortality From Breast Cancer in Men.
Suleiman Alfred Massarweh, George W Sledge, Dave P Miller, Debbie McCullough, Valentina I Petkov, Steven Shak

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, Bernard Asselain, Frederick L Baehner, Pierre Fumoleau, Steven Shak

BMC Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Eleftherios P Mamounas, Gong Tang, Soonmyung Paik, Frederick L Baehner, Qing Liu, Steven Shak

Breast Cancer Res Treat· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, Shulamith Rizel, David B Geffen, Bella Nisenbaum, Steven Shak

NPJ Breast Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, Shulamith Rizel, Lior Soussan-Gutman, Noa Ben-Baruch, Steven Shak

NPJ Breast Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis